Abstract

A series of new coumarin-N-heterocyclic hybrids, coumarin-quinolines 7a–e, coumarin-acridines 10b,c and coumarin-neocryptolepines 13b,c were synthesized and evaluated for their anticancer and antimicrobial activities. The structures of all synthesized hybrids were confirmed by FT-IR, 1H-NMR, 13C-NMR, and MS spectrometry. The anti-proliferative activity of hybrids 7a–e, 10c and 13c were bio-evaluated using MTT-assay against colon (CaCo-2), lung (A549), breast (MDA-MB-231), and hepatocellular carcinoma (HepG-2) human cancer cell lines using doxorubicin as a reference drug. The results demonstrated that, all hybrids displayed moderate to good anti-proliferative activity against the cell lines. The most active hybrids were 7a–d and 10c against CaCo-2 cancer cell line with IC50: 57.1, 52.78, 57.29, 51.95 and 56.74 µM, and selectivity index 1.38, 1.76, 2.6, 1.96 and 0.77; respectively. While, 7a,d were potent against A549 cancer cell line with IC50: 51.72, 54.8 µM and selectivity index 1.5, 0.67; respectively. Moreover, 7c showed the most potency against MDA-MB-231 cancer cell line with IC50: 50.96 µM and selectivity index 2.20. Interestingly, docking results revealed that binding energy of the current compounds showed marked affinity values ranging from -6.54 to -5.56 kcal with interactions with the reported key amino acid SER 79. Furthermore, the antimicrobial activity of the synthesized hybrids 7a–e, 10b,c, 13b and 13c were evaluated against Gram‐positive and Gram‐negative bacterial and fungal strains. The hybrids 10b, 13b, 10c, and 13c exhibited broad-spectrum antibacterial activity against E.coli, S. mutans, and S. aureus with MIC from 3.2 to 66 µM, this hybrids also displayed antifungal activity against C. albicans with MIC values ranging from 0.0011 to 29.5 µM. In-silico investigation of the pharmacokinetic properties indicated that tested hybrids had high GI absorption, low Blood Brain Barrier (BBB) permeability in addition to cell membrane penetrability.

Details

Title
Synthesis and in-vitro anti-proliferative with antimicrobial activity of new coumarin containing heterocycles hybrids
Author
Abdelaziz, Eman 1 ; El-Deeb, Nehal M. 2 ; Zayed, Mervat F. 1 ; Hasanein, Asmaa Mohammed 1 ; El Sayed, Ibrahim El-T. 1 ; Elmongy, Elshaymaa I. 3 ; Kamoun, Elbadawy A. 4 

 Menoufia University, Department of Chemistry, Faculty of Science, Menoufia, Egypt (GRID:grid.411775.1) (ISNI:0000 0004 0621 4712) 
 Genetic Engineering and Biotechnology Research Institute (GEBRI) City of Scientific Research and Technological Applications (SRTA-City) Alexandria, Biopharmaceutical Products Research Department, New Borg El-Arab City, Egypt (GRID:grid.420020.4) (ISNI:0000 0004 0483 2576) 
 Helwan University, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo, Egypt (GRID:grid.412093.d) (ISNI:0000 0000 9853 2750) 
 City of Scientific Research and Technological Applications (SRTA-City, Polymeric Materials Research Department, Advanced Technology and New Materials Research Institute (ATNMRI), Alexandria, New Borg El-Arab City, Egypt (GRID:grid.420020.4) (ISNI:0000 0004 0483 2576); The British University in Egypt (BUE), Nanotechnology Research Center (NTRC), El-Sherouk City, Cairo, Egypt (GRID:grid.440862.c) (ISNI:0000 0004 0377 5514) 
Pages
22791
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2904031430
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.